Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.
Highlights from the year included:
- 4% organic sales growth, with strong profitability and strengthened market positions.
- Strategic global expansion, including an initiated €115 million investment to expand manufacturing capacity at Brunswick, USA; the commencement of Mölnlycke’s first wound care manufacturing site in China; and ProcedurePak® tray production in Saudi Arabia and Thailand.
- Progress as a sustainability leader, with an EcoVadis platinum rating for the second consecutive year (top 1% globally), validated Net Zero targets and an 18% reduction in greenhouse gas emissions across the entire value chain, compared to 2021 baseline.
- New insights from The 2025 Non-Value Report, highlighting how hospital operating room inefficiencies impact patient safety, staff wellbeing and sustainable healthcare progress.
- Launch of iMpact30+ transformation programme to protect profitability long-term, improve efficiency and build capacity for future investments.
“2025 proved that focused execution and staying close to customers drive results, especially in a turbulent external environment. We’re growing our core business, conquering new markets and transforming how we operate, all while supporting healthcare systems under tremendous pressure to deliver better, more sustainable care,” says Guillaume Joucla, interim CEO, Mölnlycke.
Read the annual report 2025 on www.molnlycke.com/corporate/about/reports/
For more information, please contact:
Latest news
-
Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
-
Martin Ma joins Mölnlycke Zhende as General Manager
In this role, Martin will lead the joint venture's operations and growth strategy in China, with responsibility for commercial execution, organisational leadership, governance and delivery of growth ambitions in one of the world's largest wound care markets.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold Strategic Partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.
-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
5 million and growing: scaling Granudacyn® production in Salzburg